NasdaqGM:BNRBiotechs
Burning Rock Biotech (BNR) Loss Reduction Trend Tests Bearish Profitability Concerns
Burning Rock Biotech (NasdaqGM:BNR) has released its latest FY 2025 numbers with third quarter revenue of C¥131.6 million and a basic EPS loss of C¥1.56, alongside net income excluding extra items of a C¥16.8 million loss. The company has seen quarterly revenue range from C¥126.0 million to C¥148.6 million across the last six reported periods, while basic EPS moved between a loss of C¥0.90 and a much steeper loss of C¥10.53 over that time, which underscores the earnings pressure behind the...